Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria. The approval is for patients 12 years and ...

Rilzabrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK), demonstrated a rapid and substantial alleviation of symptoms in patients with chronic spontaneous urticaria (CSU) unresponsive to ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (“CSU”) in adults and adolescents aged 12 years ...

some patients may have concomitant chronic inducible urticaria. For type IIb disease, patients are more often women, exhibit frequent comorbid autoimmune diseases, have low total IgE levels ...

Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug Administration (FDA) for treating chronic spontaneous urticaria (CSU ...

“The step-by-step management of chronic spontaneous urticaria (CSU) is documented in different international guidelines, but there are 2 related and vital points that have been poorly discussed ...